IMU (ASX) Prediction

Originally posted by Martin288: ↑

Now I know there is some levity in what the future will be like for IMU and its share price.
I have the optimism bias as well. Not game to put a number on it but

Just remember we have some collaborative trials going with some really large players. That is grounds for huge optimisim if you just belive that some of the up to ten trials show positive results. This could result in huge gains or not. I am optmistic sI think more than half of the trials will be successful and deals will come at end of stage 2 trials of each collaboration. Yes optimistic I know but thats supposed to be the aim.
I also note time is ticking . IMU doe snot have forever on its B cell technology. It has first mover advantage but I am giving it five years to make or break. It could be even sooner as other technology has caught on and breaking new ground too.

Example of our huge opportunity.

One example
If the Keytruda trial in combo with Hervaxx shows promise with the trial primary end point finishing July 2023 and trial finishing in Nov 2025 then we are in the middle of a very important stage 2 trial our very own Hervaxx. Keytruda was one of the biggest selling cancer drug off patent looking for options and chose Hervaxx. I am excited for the results as well as the possible commercial beenfit to IMU and shareholders.

So by partnering with some the largest pharmaceuticals we are on the cusp. If the Hervaxx drug is of benefit to patients then why wouldnt Keytruda owners Merck offer to purchase or license Hervaxx for its patients and Merck benefit.
Keytruda sales climbed to $20.94 billion, up 22 percent from $17.19 billion in 2021. So these are big players. It will be a big deal if Merck want to use IMU Hervaxx in future combo with its patients.

For levity sake As IMU drug can be made for one tenth of existing drugs lets say Hervax sales equivelant in combo for Hervaxx is $2 billion per year for say 15 years (2038) patent expiry. So valuation on fictional valuation on fictional deal done makes Value of Hervaxx worth $30billion. So lets say Merck get it for a bargain $10billion. Thats $2.00 per share on Hervaxx.

So yes the excitement should be there as this has very big consequences for IMU.
Why not us? Why not Hervaxx if trials results great! Bring on JUly-Sep 2023 results!

Hang in there shareholders. Its a very exciting time and just remember we have the best scientists in the world collaborating for good reason. They want this to work for the benefit of its patients and its shareholders.
GLTA shareholders

Expand

I am with you on Hervaxx possibilities, However just note that the timeline has been delayed by 6- 12 months. That is I think the JULY interim readout for Hervaxx, probably looks more like - end of year early 2024. Why?

Firstly... Next horizon - is a very hard study to enrol - see here for a quote from LC back in March preso https://hotcopper.com.au/threads/why-imu-is-a-multi-multi-bagger.5431324/page-13448?post_id=68053267
Secondly, they have only ONE hospital for enrolment.
Thirdly they mentioned they were looking for more hospitals in Dec 2022, this is yet to happen.
Fourthly - their Newish (May 23 it was put out) table of expected order of inflection points seems to reflect this delay...HErvaxx is down the list

I wrote about this earlier just here....https://hotcopper.com.au/threads/why-imu-is-a-multi-multi-bagger.5431324/page-13446?post_id=68052753

DYOR and all that.

No.	Vol.	Price($)
12	819340	5.5¢

No.

Vol.

Price($)

819340

5.5¢

Price($)	Vol.	No.
5.6¢	515951	4

Price($)

Vol.

No.

5.6¢

515951

No.	Vol.	Price($)
10	736340	0.055
29	2959163	0.054
17	1584508	0.053
19	1719511	0.052
22	3589607	0.051

No.

Vol.

Price($)

736340

0.055

2959163

0.054

1584508

0.053

1719511

0.052

3589607

0.051

Price($)	Vol.	No.
0.056	515951	4
0.057	1117035	10
0.058	1866575	10
0.059	2264940	6
0.060	1912026	16

Price($)

Vol.

No.

0.056

515951

0.057

1117035

0.058

1866575

0.059

2264940

0.060

1912026

(20min delay)
Last 5.5¢		Change -0.004(6.78%)		Mkt cap ! $402.5M

Open	High	Low	Value	Volume
6.0¢	6.1¢	5.5¢	$2.515M	44.29M

Prediction, page-27

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Strike Energy secures $153 million for Perth Basin gas projects

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Cultural heritage agreement puts Walford Creek exploration back on the map

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Prediction, page-27

Top Stories

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Strike Energy secures $153 million for Perth Basin gas projects

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Cultural heritage agreement puts Walford Creek exploration back on the map

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News